Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07653269

Predicting Risk of Progression of Early to Late AMD in the Aging Eye Through Imaging and Multimodal Evaluation

The purpose of this research study is to evaluate a new screening procedure for the early detection and monitoring of Age-related Macular Degeneration (AMD) in community settings and community hospital settings, to identify associated risk factors, and develop personalized monitoring strategies for at-risk individuals throughout the 5 years follow up period, which will allow us to establish prevalence, natural history of progression of early AMD in the community.

Recruiting

Interested in participating?

Request Info

Key information

Age range

55 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Outram Community Hospital, Singapore

Loading trial locations.

About this study

An effective screening programme requires several key components to be successful. First, the natural history of the condition needs to be well understood. Next, a clear threshold for referral must be established and finally, effective intervention must be available to treat the condition in question. In ophthalmology, the most effective screening programme we have is for diabetic retinopathy (DR). Here, the natural history and thresholds are well established, and treatment in the form of pan-retinal photocoagulation is effective in preventing progression to visually threatening DR.

While there is consensus regarding features that predispose to late AMD, at an individual level, risk, rate and pattern of progression remain unpredictable therefore there is a need to develop effective AMD screening. This is in contrast to diabetic retinopathy because the natural history is well understood and the risk of vision loss increases sharply in those with referrable DR. In AMD, this threshold is not yet established.

As there is currently no standardized screening protocol for early AMD, especially in the community-based setting and community hospital settings, our study aims to understand the natural progression of AMD in the elderly and establish a referrable threshold before visually threatening AMD occurs. This will ultimately inform a comprehensive and standardized community-based screening approach for AMD.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 55 years or older
  • No severe systemic illnesses that prevent study participation
  • Willing and able to undergo protocol-required procedures for both eyes
  • Willing and able to provide written informed consent

Exclusion criteria

  • Systemic disorders that preclude reliable clinical examination or multimodal imaging
  • Poor compliance or severe mental illness that hinders participation
  • Persons who are unable to give informed consent

Treatment and study plan

Primary outcomes

  1. To establish the natural history of AMD in Asian elderly and to identify clinical multimodal imaging, genetic, and metabolomic predictors of progression.

    Time frame: 3 years

    Progression is defined as the change from early signs of AMD to advanced AMD.

Study contacts

Contact information is provided by the study sponsor or research team.

Gemmy Cheung Professor

CONTACT

[email protected]

+6563224500

Sponsors and collaborators

Lead sponsor

Singapore National Eye Centre

Other Gov

Collaborators

  • Singapore Health Services

Registry information

Official study title

Predicting Risk of Progression of Early to Late AMD in the Aging Eye Through Imaging and Multimodal Evaluation - PRIME Study

Acronym: PRIME

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Jun 17, 2026
Registry last updated
Jun 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.